TORL BioTherapeutics closed an oversubscribed $158M Series B-2 financing round to advance clinical development of its novel antibody-drug conjugate oncology pipeline.
TORL BioTherapeutics closed an oversubscribed $158M Series B-2 financing round to advance clinical development of its novel antibody-drug conjugate oncology pipeline.
04/10/24, 2:11 PM
Location
culver cityMoney raised
$158 million
Industry
biopharma
therapeutics
pharmaceutical
biotechnology
health care
Round Type
series b
TORL BioTherapeutics has closed an oversubscribed $158M Series B-2 financing round, with the proceeds intended for advancing the clinical development of its novel antibody-drug conjugate oncology pipeline.
Company Info
Location
culver city, california, united states
Additional Info
TORL BioTherapeutics is building a preeminent biopharmaceutical company dedicated to the discovery, development, and commercialization of antibody-based therapies to improve and extend the lives of people with cancer worldwide. Through a strategic partnership with the Slamon Research Lab at UCLA, TORL has exclusive development and commercial rights to a large program of biologics-based drugs for promising, and novel cancer targets.